Feasibility and short-term outcomes of transcatheter valve-in-valve implantation for failed aortic and mitral bioprosthesis-a single-center experience
Wei-Hsian YIN
Yung-Tsai LEE
Tien-Ping TSAO
Kuo-Chen LEE
Ho-Ping YU
Ming-Chon HSIUNG
Jeng WEI
摘要：Objectives Transcatheter valve-in-valve (VIV) implantation for failed bioprostheses has become an alternative to open surgery in those deemed high risk.The purpose of this study was to evaluate the effectiveness and outcomes of this emerging procedure.Methods Fourty V1V procedures were performed in 38 consecutive patients (mean age 70 ± 14 years and mean Logistic EuroScore 23.6 ± 15.5％) with severe aortic (n =19) or mitral (n =21) bioprosthetic valve dysfunction between 2014 and 2017.Bioprosthetic failure was secondary to stenosis in 11 (27.5％),regurgitation in 19 (47.5％),and combined in 10 (25.0％) bioprostheses.Clinical,echocardiographic,and procedural profiles were characterized,and the short-term results of the study patients were reported.Results Successful transfemoral (n =15),trans-subclavian (n =1),or transapical (n =3) aortic VIV using either balloon-expandable valves (Edwards Sapien XT,n =7) or self-expandable valves (Medtronic CoreValve,n =12);and tmnsapical (n =21) mitml VIV using either Edwards Sapien XT (n =15) or mechanically expandable valves (Boston Scientific Lotus,n =6) were accomplished in all 40 VIV procedures.Implantation was successful with immediate restoration of satisfactory valve function in all patients.Five patients (13.2％) died at a median follow up of 9.3 months.Most of the 33 patients alive were in good functional status with good prosthetic valve performance.Conclusions Transcatheter VIV implantation is a feasible and safe option for the management of bioprosthetic valve failure.It may offer a less invasive alternative for those high-risk patients needing repeat valve replacement.
机标关键词：
论文发表日期：2018-07-19
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：10( 486-495 )
英文信息